Approval status
Retatrutide FDA approval status
As checked on May 2, 2026, retatrutide is not FDA approved for public sale or prescription. Lilly describes retatrutide as investigational, and FDA says retatrutide is not a component of an FDA-approved drug.
Key takeaways
- Retatrutide is investigational and not FDA approved for public sale or prescription.
- FDA says retatrutide is not a component of an FDA-approved drug.
- Lilly says retatrutide is not yet available for public use.
- Public listings should be read as source-page claims, not approval or access signals.
What FDA says
FDA's GLP-1 safety page says retatrutide and cagrilintide cannot be used in compounding under federal law, are not components of FDA-approved drugs, and have not been found safe and effective for any condition.
FDA also warns that some products sold online as retatrutide and labeled for research use may be unapproved drugs marketed to consumers, with unknown quality and potential harm.
Source: FDA GLP-1 safety page
What Lilly says
Lilly says retatrutide is investigational, not yet available for public use, and legally available only to participants in Lilly clinical trials while safety and efficacy are being evaluated.
Source: Lilly retatrutide FAQ
What this means for this site
Retatrutide Public Source Tracker documents public-page claims for regulatory awareness. It does not rank sellers, recommend sources, or provide purchase guidance.
Sources
Public record review
Have a public record we should add?
Submit a public page, correction, or observation for documentation review. Submissions are evaluated for public-record value only, not to help people obtain products.